MKI67 and lung carcinoma: Similar to persister and DTEP cells (Extended Data Fig. 6l), both the on-treatment melanoma and residual disease lung cancer samples have decreased expression of proliferation marker Ki-67 (Extended Data Fig. 10e,f), whereas progressive disease tumours have high levels of Ki-67 (Extended Data Fig. 10f).